FGF-23 Levels in Patients with AKI and Risk of Adverse Outcomes
Authors:
- 1 August 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 7 (8) , 1217-1223
Abstract
Summary: Background and objectives: Fibroblast growth factor 23 plays an important role in regulating phosphate and vitamin D homeostasis. Elevated levels of fibroblast growth factor 23 are independently associated with mortality in patients with CKD and ESRD. Whether fibroblast growth factor 23 levels are elevated and associated with adverse outcomes in patients with AKI has not been studied. Design, setting, participants, & measurements: This study had 30 participants with AKI, which was defined as an increase in serum creatinine≥0.3 mg/dl or ≥50% from baseline, and 30 controls from the general hospital wards and intensive care units. Plasma levels of C-terminal fibroblast growth factor 23 and vitamin D metabolites were measured within 24 hours of AKI onset and 5 days later. The composite endpoint was death or need for renal replacement therapy. Results: Enrollment fibroblast growth factor 23 levels were significantly higher among participants with AKI than controls (median [interquartile range]=1471 [224–2534] versus 263 [96–574] RU/ml, P=0.003). Enrollment fibroblast growth factor 23 correlated negatively with 25-hydroxyvitamin D (r=−0.43, Pr=−0.39, P=0.003) and positively with phosphate (r=0.32, P=0.02) and parathyroid hormone (r=0.37, P=0.005). Among participants with AKI, enrollment fibroblast growth factor 23 (but not other serum parameters) was significantly associated with the composite endpoint, even after adjusting for age and enrollment serum creatinine (11 events; adjusted odds ratio per 1 SD higher ln[fibroblast growth factor 23]=13.73, 95% confidence interval=1.75–107.50). Conclusions: Among patients with AKI, fibroblast growth factor 23 levels are elevated and associated with greater risk of death or need for renal replacement therapy.Keywords
This publication has 21 references indexed in Scilit:
- Fibroblast Growth Factor 23 in Patients Undergoing Peritoneal DialysisClinical Journal of the American Society of Nephrology, 2011
- FGF23 induces left ventricular hypertrophyJournal of Clinical Investigation, 2011
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- FGF-23 and PTH levels in patients with acute kidney injury: A cross-sectional case series studyAnnals of Intensive Care, 2011
- Elevated FGF-23 in a patient with rhabdomyolysis-induced acute kidney injuryNephrology Dialysis Transplantation, 2009
- Parathyroid Hormone Regulates Fibroblast Growth Factor-23 in a Mouse Model of Primary HyperparathyroidismJournal of the American Society of Nephrology, 2007
- Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2007
- Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injuryCritical Care, 2007
- Phosphatonins and the Regulation of Phosphate HomeostasisAnnual Review of Physiology, 2007
- Role of the vitamin D receptor in FGF23 action on phosphate metabolismBiochemical Journal, 2005